• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.925 -0.015 (-0.77%)
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,157,725
Open 1.960
Bid (Size) 1.900 (100)
Ask (Size) 1.990 (500)
Prev. Close 1.940
Today's Range 1.910 - 1.995
52wk Range 0.9500 - 3.230
Shares Outstanding 98,384,456
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
October 12, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 40.4% below 52-week high
1.925
0.9552W Low 3.2352W High
1 Week 15.4% below 1-week high
1.891W Low 2.271W High

Fate Therapeutics, Inc. - Common Stock (FATE) traded between $0.95 and $3.23 over the past 52 weeks and last traded at $1.93, 40.4% below its 52-week high. Over the past week it ranged between $1.89 and $2.27.

Past 12 Months
-9.6%
-17.7%
-35.6%
+49.2%
+95.2%
+28.3%
1W -$0.20
1M -$0.41
3M -$1.07
6M +$0.64
YTD +$0.94
1Y +$0.43

FATE was +28.3% over the past year, +49.2% over six months, +95.2% year to date, -9.6% in the last week.

12 Months vs Market
FATE
+28.3%
DIA
+12.6%
SPY
+16.5%
QQQ
+21.7%
IWM
+11.0%

Over the past 12 months FATE returned +28.3% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.5%, QQQ (Nasdaq 100) +21.7% and IWM (Russell 2000) +11.0%.

Volume & Liquidity 0.69× 3-mo avg
Today 1,157,725 3-mo avg 1.7M
1W
1.1M
1M
1.6M
3M
1.7M
6M
2.8M
YTD
2.4M
1Y
2.2M

FATE most recently traded 1,157,725 shares against a 3-month average daily volume of 1.7M.

More News

Read More
News headline image
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
October 01, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
September 25, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
September 16, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
September 09, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
September 03, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
August 31, 2026
Via The Motley Fool
News headline image
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
August 14, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
August 13, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
July 09, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
July 06, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
July 01, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Appoints Laura Hamill to Board of Directors
June 15, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
June 12, 2026
From Equity Insider
Via GlobeNewswire
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 08, 2026
From Biotech Insider
Via GlobeNewswire
News headline image
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
June 04, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
June 01, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
May 21, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
May 20, 2026
Via FinancialNewsMedia
News headline image
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
May 14, 2026
Via FinancialNewsMedia
News headline image
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 13, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
May 11, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Fate Therapeutics, Inc. - Common Stock publicly traded?
Yes, Fate Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Fate Therapeutics, Inc. - Common Stock trade on?
Fate Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fate Therapeutics, Inc. - Common Stock?
The ticker symbol for Fate Therapeutics, Inc. - Common Stock is FATE on the Nasdaq Stock Market
What is the current price of Fate Therapeutics, Inc. - Common Stock?
The current price of Fate Therapeutics, Inc. - Common Stock is 1.925
When was Fate Therapeutics, Inc. - Common Stock last traded?
The last trade of Fate Therapeutics, Inc. - Common Stock was at 10/15/26 04:00 PM ET
What is the market capitalization of Fate Therapeutics, Inc. - Common Stock?
The market capitalization of Fate Therapeutics, Inc. - Common Stock is 189.39M
How many shares of Fate Therapeutics, Inc. - Common Stock are outstanding?
Fate Therapeutics, Inc. - Common Stock has 189M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap